HEC211909 / HEC Pharm - LARVOL DELTA

Preclinical studies of HEC211909, an orally bioavailable, high potent pan-KRAS inhibitor (AACR 2025) - "HEC211909 is a highly potent and selective orally pan-KRAS(ON/OFF) inhibitor against KRAS G12D, KRAS G12C, KRAS G12V, KRAS Q61H, KRAS G13D mutations and also displays high selectivity over WT HRAS and NRAS, thus providing an expanded therapeutic index."

Preclinical • Oncology • Pancreatic Cancer • Solid Tumor • HRAS • KRAS • NRAS